The FIP1L1-PDGFRA fusion gene is a recurrent molecular abnormality in patients with eosinophilia-associated myeloproliferative neoplasms. We characterized FIP1L1-PDGFRA junction sequences from 113 patients at the mRNA (n ¼ 113) and genomic DNA (n ¼ 85) levels. Transcript types could be assigned in 109 patients as type A (n ¼ 50, 46%) or B (n ¼ 47, 43%), which were created by cryptic acceptor splice sites in different introns of FIP1L1 (type A) or within PDGFRA exon 12 (type B). We also characterized a new transcript type C (n ¼ 12, 11%) in which both genomic breakpoints fell within coding sequences creating a hybrid exon without use of a cryptic acceptor splice site. The location of genomic breakpoints within PDGFRA and the availability of AG splice sites determine the transcript type and restrict the FIP1L1 exons used for the creation of the fusion. Stretches of overlapping sequences were identified at the genomic junction site, suggesting that the FIP1L1-PDGFRA fusion is created by illegitimate non-homologous end-joining. Statistical analyses provided evidence for clustering of breakpoints within FIP1L1 that may be related to DNA-or chromatin-related structural features. The variability in the anatomy of the FIP1L1-PDGFRA fusion has important implications for strategies to detect the fusion at diagnosis or for monitoring response to treatment.
Introduction
The FIP1L1-PDGFRA fusion gene results from a cytogenetically invisible interstitial chromosomal deletion on chromosome band 4q12 and was identified as a recurrent molecular abnormality in patients with eosinophilia-associated myeloproliferative neoplasms (Eos-MPNs) diagnosed earlier as hypereosinophilic syndrome, chronic eosinophilic leukemia or systemic mastocytosis with eosinophilia. [1] [2] [3] [4] The pathogenesis of FIP1L1-PDGFRA-positive Eos-MPN is similar to BCR-ABLpositive chronic myeloid leukemia with constitutively increased tyrosine kinase activity of the fusion protein, potential evolution from chronic phase disease to blast crisis/secondary acute myeloid leukemia and excellent response to treatment with imatinib. [1] [2] [3] [4] [5] [6] [7] [8] [9] As the underlying deletion at 4q12 is invisible by conventional karyotyping, 1 fluorescence in situ hybridization or reverse transcriptase-(RT)-PCR is typically used to detect the fusion gene.
1,2 Sequence analysis of amplified products obtained by PCR allows detailed characterization of the heterogeneous FIP1L1-PDGFRA junction sequences at both DNA and mRNA levels. The genomic breakpoints within FIP1L1 have been reported to occur in five different introns (introns 9-13; http://www.ensembl.org), whereas the genomic breakpoints within PDGFRA are exclusively found within exon 12. Two different types of fusion mRNA can be distinguished: type A fusions result from the use of a cryptic splice acceptor site in an FIP1L1 intron and type B fusions result from the use of a cryptic splice acceptor site in PDGFRA exon 12.
1 Moreover, heterogeneity is increased by the insertion of FIP1L1 intron-derived nucleotides in type A fusion mRNAs. However, the number of cases reported to date is too low to draw any conclusion about the relative prevalence of the different fusion transcripts or likely mechanisms underlying formation of the causative intrachromosomal deletion.
Here, we report on a large cohort of patients, which was collected from several European laboratories within the framework of the European LeukemiaNet. We present data on (i) the identification of several new individual fusion transcripts that are of diagnostic significance, (ii) characterization of the anatomy of three general types of fusion transcripts, (iii) detailed analysis of the great variability of fusion transcripts and (iv) evidence that the fusion gene is created by illegitimate nonhomologous end-joining (NHEJ) after DNA breakage. These results have important implications for diagnosis and development of sensitive assays for the monitoring of residual disease in FIP1L1-PDGFRA-positive patients during treatment.
Materials and methods

Patients
Bone marrow and peripheral blood samples from 113 patients with FIP1L1-PDGFRA-positive Eos-MPN were analyzed. Informed consent was obtained from individual patients according to the Declaration of Helsinki.
Reverse transcription-PCR
Total leukocyte RNA was extracted and reverse transcribed with random hexamers using standard techniques. The quality of cDNA was tested by the amplification of standard genes, for example, ABL1, BCR or glucose-6-phosphate dehydrogenase (G6PD). Primers for the amplification of the FIP1L1-PDGFRA fusion gene by nested reverse transcription (RT)-PCR were used as published.
1,10
Genomic long-template PCR A single set of reverse primers derived from PDGFRA intron 12 was used in combination with various forward FIP1L1 primers, which were selected according to the fusion sequence on the RNA level. The long-template PCR reactions were performed following the manufacturer's instructions (Roche Diagnostics, Mannheim, Germany). Primer sequences are listed in Supplementary Table 1 .
Bubble-PCR
Bubble-PCR to amplify genomic junction fragments was carried out essentially as described using reverse primers derived from PDGFRA intron 13 and bubble-specific primers. 10 
Sequence analysis
PCR products were sequenced either directly or after cloning using the TOPO cloning kit (Invitrogen, Leiden, The Netherlands). The exon numbering was according to ENSEMBL transcript ENST00000337488, which contains 18 exons. Numbering of exons 9-13 is therefore different from the initial numbering reported by Cools et al.
1 in which exons 7a, 8, 8a, 9 and 10 correspond to exons 9, 10, 11, 12 and 13 in this study. The exon numbering terminology and corresponding flanking sequences can be found in Figure 1a and Supplementary  Table 2 .
Analysis of breakpoint features
Possible clustering of FIP1L1 breakpoints was assessed using scan statistics, which determines the likelihood of a number of breakpoints falling within a certain sliding 'window' along a breakpoint cluster region, known as a bandwidth. P-values are calculated by comparing the density of breakpoints falling within a bandwidth with a projected homogeneous distribution across the same area. 11 The size of the bandwidth can greatly influence the significance of a cluster and therefore we used several methods described in Segal and Wiemels.
12 Known DNA sequence or structural features (Supplementary Table 3) were mapped along the breakpoint cluster regions using EMBOSS/Fuzznuc or custom Perl scripts. Statistical proximity of breakpoints was determined by comparing the observed proximity of breakpoints to these features to 200 random simulations of the dispersal of breakpoints and the features within the space of the target breakpoint regions.
Results
FIP1L1-PDGFRA mRNA fusions
FIP1L1-PDGFRA fusion transcripts were amplified from all 113 patients by nested RT-PCR (Supplementary Table 4 ). Nine different FIP1L1 exons (exons 9-16 and 18) were found to be fused with PDGFRA exon 12 that was truncated in all cases to a variable degree (Figure 1a ).
FIP1L1-PDGFRA genomic breakpoints
From 85 of the 113 patients, genomic DNA of adequate quality was available. The genomic breakpoints in those 85 patients were successfully identified by long-template and/or bubble PCR (Supplementary Table 4 ). Within FIP1L1, genomic breakpoints were identified within a sequence stretch of 60 kb ranging from intron 9 to 16. Breakpoints were predominantly located in FIP1L1 intron 10 (n ¼ 18, 21%), intron 11 (n ¼ 22, 26%), intron 12 (n ¼ 10, 12%) or intron 13 (n ¼ 16, 19%). Rarely, genomic breakpoints were found in FIP1L1 intron 9 (n ¼ 3, 3%), exon 11 (n ¼ 1, 1%), exon 12 (n ¼ 4, 4%), exon 13 (n ¼ 3, 3%), exon 14 (n ¼ 1, 1%), intron 14 (n ¼ 1, 1%), intron 15 (n ¼ 2, 2%), exon 16 (n ¼ 2, 2%) or intron 16 (n ¼ 2, 2%). All genomic PDGFRA breakpoints fell exclusively within exon 12 between positions þ 13 and þ 106 with most (65/85; 76%) being found between positions þ 27 and þ 84 (position þ 1 refers to the first base in exon 12). In the majority of patients (55/85; 65%), genomic breakpoints could not be determined with absolute precision because of short stretches (1-5 bp) of homology between the two genes.
Classification of three different transcript types
The usage of different AG acceptor splice sites and the variable insertion of FIP1L1 intron-derived sequences of different length Transcript type A. Transcript type A was identified in 50 patients (46%) and is characterized by the insertion of a sequence between an intact FIP1L1 exon and a truncated PDGFRA exon 12. The inserted sequences were variable in length (2-76 bp) and originated in all but one of 50 patients (98%) from the intron immediately downstream of the relevant FIP1L1 exon. The inserted sequence was always preceded by an AG splice acceptor site at the genomic level. The junction sequence between FIP1L1 and PDGFRA are therefore identical at the DNA and mRNA levels as the 3 0 -end of the inserted sequence corresponds to the genomic FIP1L1 breakpoint. Strikingly, of the 17 patients with mRNA fusions involving FIP1L1 exon 12, only one was type A, whereas none of the 21 patients with involvement of FIP1L1 exon 13 was type B with the majority of them being type A (17/21; 81%).
Atypical inserts were seen in three patients. One patient had an insert of 76 bp that was derived from two distinct regions of the same FIP1L1 intron 13 as illustrated in Figure 3 . The second patient had an inserted sequence of 43 bp that was partly derived from chromosome band 4q33, indicating a complex rearrangement. The third patient had a transcript type A-like insertion of a FIP1L1 intron-derived sequence fused with a truncated FIP1L1 exon 16 ( Figure 3 ). The variability of the FIP1L1 exons that were involved, the length and origin of inserts, and the length of the truncated PDGFRA exon 12, all lead to formation of unique FIP1L1-PDGFRA junction sequences in each individual with a type A junction.
Transcript type B. Transcript type B was identified in 47 patients (43%) and was characterized in the majority of patients (n ¼ 43) by an mRNA fusion consisting of a normally spliced FIP1L1 exon fused with a PDGFRA sequence located immediately downstream of the first cryptic AG splice acceptor site following the genomic breakpoint within PDGFRA exon 12 ( Figure 4 ). Between PDGFRA exon 12 positions þ 13 and þ 106, there are five AG dinucleotides located at positions þ 25/26, þ 43/44, þ 48/49, þ 83/84 and þ 100/101. The usage of these potential cryptic splice sites was þ 25/26 (4/43 patients; 9%), þ 43/44 (22/43; 51%), þ 48/49 (0%), þ 83/84 (13/43, 30%) and þ 100/101 (4/43, 9%). Because of the constraints dictated by the different reading frames, the sites at þ 25/26, þ 43/44 and þ 100/101 were only used in combination with FIP1L1 exons 10 and 11, whereas þ 83/84 was almost exclusively used in combination with FIP1L1 exon 12 (12/13, 92%). None of the four AG splice sites within the PDGFRA breakpoint cluster region, which are usually used for transcript type B, creates an in-frame fusion with FIP1L1 exon 13. Although the AG at position þ 48/49 is in-frame, this is not used as a splice site with any of the available FIP1L1 exons, presumably because it is not recognized by the splicing machinery.
Two patients with involvement of FIP1L1 exon 11 showed PDGFRA breakpoints in the region between þ 45 and þ 84. As mentioned above, the next AG splice site following this region can regularly create only an open-reading frame with FIP1L1 exon 12. One of these transcripts is a special type B transcript with usage of an AG splice site located at the end of the FIP1L1 intron. The second patient has a sequence variant in PDGFRA exon 12 at position 83, in which the A of the AG splice site is substituted by a G and thus the next AG after the breakpoint in this patient is at þ 100/101. When compared with the original sequence in ENSEMBL, 25 of 26 evaluable patients had a G instead of an A at position þ 48 of PDGFRA exon 12 leading to a substitution from a glutamine to arginine. The genomic PDGFRA breakpoint is located between 0 and 35 bp upstream of the PDGFRA AG splice site. The junction sequences at the DNA Anatomy of the FIP1L1-PDGFRA fusion gene C Walz et al and mRNA levels in the same individual are therefore different, but identical fusion transcripts are found in different patients, for example, fusion of FIP1L1 exon 10 or 11 to PDGFRA exon 12 position þ 45 was seen in a total of 22 patients, 11 for each FIP1L1 exon. Transcript type B was not observed with involvement of FIP1L1 exon 13 because this exon cannot create an in-frame fusion with available AG splice sites of PDGFRA exon 12. In one unusual case, the AG splice site was not located in PDGFRA but was provided by the end of the intronic FIP1L1 sequence immediately upstream of the breakpoint, whereas in the remaining three patients the A was derived from the intronic FIP1L1 sequence and the G from the exonic PDGFRA sequence.
Transcript type C. Transcript type C was identified in 12 patients (11%) in which both genomic breakpoints fell within coding sequences creating a hybrid exon without use of a cryptic acceptor splice site (exon 11, n ¼ 1; exon 12, n ¼ 4; exon 13, n ¼ 4; exon 14, n ¼ 1; exon 16, n ¼ 1 and exon 18, n ¼ 1). An additional four patients could not be assigned to either transcript type B or C because of lack of DNA. These patients are probably transcript type C but could possibly have been transcript type B if the AG splice site is provided by the end of the FIP1L1 intron or by an AG overlap, as seen in the three patients described in the previous paragraph.
The location of breakpoints within PDGFRA exon 12 determines the transcript type For the assessment of the breakpoint distribution in PDGFRA exon 12, data from 109 patients were available: 85 that were directly amplified from genomic DNA and a further 24 (transcript type A: n ¼ 4; type B: n ¼ 18; type C: n ¼ 2) for whom the breakpoint could be inferred from the mRNA fusion. The borders of various genomic breakpoint regions were defined by the location of the AG splice sites that are capable of maintaining an in-frame fusion. Breakpoints were located between þ 13 and þ 26 of PDGFRA exon 12 for 11 (10%) patients (region 1), between þ 27 and þ 44 for 27 (25%) patients (region 2), between þ 45 and þ 84 for 58 (53%) patients (region 3) and between þ 85 and þ 101 for 11 (10%) patients (region 4), respectively. Two patients showed breakpoints at þ 105 or þ 106.
In regions 1 ( þ 13-26) and 4 ( þ 85-101) of PDGFRA exon 12, the numbers of patients were too small to draw significant conclusions. Breakpoints in region 2 ( þ 27-44) generated type B transcripts in the majority of patients (22/27, 82%) and involved only FIP1L1 exons 10 and 11. Breakpoints in region 3 ( þ 45-84) gave rise to the majority of type A transcripts (40/50, 80%) with predominant involvement of FIP1L1 exons 10, 11 and 13 (33/40, 83%). Of interest, the type B transcripts associated with breakpoints in this region almost exclusively involved FIP1L1 exon 12 (12/13, 92%). Conversely, only one patient involving FIP1L1 exon 12 led to formation of a type A transcript ( Table 1) .
Clustering of breakpoints
We used scan statistics to determine the statistical significance of clustering. This procedure involves choosing a length of sequence, termed a 'bandwidth', and sliding this window along the breakpoint cluster regions. The frequency of breakpoints falling within the window is compared to a random distribution of breakpoints; if this number exceeds a defined threshold, then statistically significant clustering is achieved. The size of the bandwidth must be chosen carefully to prevent artifactual significance; for this reason, we used several statistical techniques to choose bandwidth, 12 and we only report results as significant when they were robust to several bandwidths. Considering breakpoints of all types together, clustering as assessed by scan statistics was significant at a bandwidth of 660 bp (P ¼ 0.01) becoming much more significant at higher bandwidths (P ¼ 8 Â 10 -6 at a bandwidth of 6323 bp). Type A breakpoints were not significant at any bandwidth but type B were highly significant (Po0.005 at bandwidths ranging from 1746 to 6915). Transcript type C breakpoints were borderline significantly clustered (P ¼ 0.06 at bandwidth of 1700) but are structurally confined to the ends of exons and therefore the clustering is dependent on mRNA structure rather than DNA sequence features. Breakpoints within PDGFRA were highly clustered overall, and among transcripts type A (P ¼ 0.01), but not for the B and C types (PB1.0). The number of clusters was assessed using a gap statistic as described.
12 FIP1L1 showed four clusters overall, and for the type B variant, two. PDGFRA demonstrated evidence for five clusters overall, and four for type A variants ( Figure 5) . A search for two-way clustering between FIP1L1 and PDGFRA breakpoints did not demonstrate significant associations.
Known DNA sequence or structural features (Supplementary  Table 3 ) were also mapped along the breakpoint cluster regions. There were no significant associations with repetitive elements (including LINE and Alu sequences); however, predicted matrix attachment regions colocalized to some degree with breakpoint cluster regions. To explore this further, 200 simulations were performed comparing the actual distribution of breakpoints and features to randomized assortments of the breakpoints and features. In this analysis, predicted scaffold/matrix attachment regions (by the SMARTest procedure 13, 14 were found to be overrepresented 100 bp prior to the breakpoints (P ¼ 0.01). Smaller known motifs, such as topoisomerase II sites, recombination site sequences and pyrimidine tracts (Supplementary Table 3 ), were Anatomy of the FIP1L1-PDGFRA fusion gene C Walz et al not represented near breakpoints more often than by chance (data not shown).
Discussion
FIP1L1-PDGFRA has emerged as the second most common fusion gene in MPNs after BCR-ABL1; however, the creation and diversity of FIP1L1-PDGFRA fusion transcripts are much more complex. Within PDGFRA, all genomic breakpoints are tightly clustered between positions þ 13 and þ 106 of exon 12, whereas breakpoints in FIP1L1 are much more dispersed. Breakpoints within the same region of exon 12 are also seen in rare cases with variant PDGFRA fusions involving alternative partner genes. 10, [15] [16] [17] Rather than PDGFRA exon 12 being a site that is particularly prone to breakage, the most likely reason for this clustering is that breakpoints in this region specifically disrupt the autoinhibitory WW-like domain between its two tryptophan residues W559 -and W586. Stover et al. 18 have shown earlier that this disruption of the WW-like domain is essential for the activation of the PDGFRA kinase by FIP1L1, which, in contrast to other TK fusion partners, is unlikely to contain a known protein dimerization domain. FIP1L1 is therefore completely dispensable for PDGFRA activation. Of interest, we identified two patients with PDGFRA breakpoints that do not disrupt the autoinhibitory WW-domain, suggesting that at least in these cases alternative mechanisms contribute to tyrosine kinase activation. Moreover, recent data have shown Figure 5 Assessment of number of clusters for FIP1L1 using gap statistics with hierarchical clustering algorithm using Euclidean distance and complete linkage. 12 The gap statistic is calculated at each number of theoretical clusters (1, 2, y5), and where the gap statistic displays the lowest value, a characteristic 'kink' in the graph is displayed; this kink corresponds to the number of clusters that is best supported by the data. In this way, one can see that FIP1L1 breakpoints overall have four clusters, whereas FIP1L1-PDGFRA transcript type B has only two clusters. Table 1 Genomic breakpoints within PDGFRA exon 12, corresponding FIP1L1 exons and transcript type Breakpoint location within PDGFRA exon 12
Gray boxes indicate breakpoints belonging to transcript type B, which cannot create an in-frame fusion with the available AG splice site.
a
The marked cases are special type B transcripts that skip the AG splice site at +83/84, which is not in-frame with FIP1L1 exon 11. The end phase of each FIP1L1 exon is listed in brackets.
Anatomy of the FIP1L1-PDGFRA fusion gene C Walz et al that FIP1L1-RARA fusion proteins form homodimers in a case of acute promyelocytic leukemia, suggesting that the dimerization of this fusion protein is presumably mediated by the FIP1L1 moiety. 19 However, more experimental studies are required to confirm these results to finally assess the impact of FIP1L1 for oncoprotein activation.
The use of various cryptic AG splice sites in FIP1L1 and PDGFRA usually determines the transcript type, which is either with (transcript type A) or without (transcript type B) an inserted sequence derived from a FIP1L1 intron. We have demonstrated that the location of genomic breakpoints within PDGFRA exon 12 is strongly associated with the FIP1L1 exons used for the creation of the fusion gene and also the transcript type. In transcript type A, any FIP1L1 exon could theoretically be involved in the creation of the fusion gene if the intron sequence between the AG splice site and the genomic breakpoint can maintain an in-frame fusion. In addition, there is a significant relationship (Pearson correlation coefficient r ¼ 0.84, P ¼ 0.0042) for transcript type A between the relative frequency of involvement of specific FIP1L1 exons and the size of the intron immediately downstream of that exon ( Figure 6 ).
The formation of transcript type B depends on the creation of an in-frame fusion between the end of a FIP1L1 exon and PDGFRA sequence preceded by a cryptic splice site. FIP1L1 exon 12 is therefore used only if the PDGFRA breakpoint is located between positions þ 45 and þ 84 as only the AG site at position þ 83/84 was found to create an in-frame fusion with FIP1L1 exon 12. The AG splice site at position þ 107/108 would theoretically be available for an in-frame fusion; however, no genomic breakpoint with creation of transcript type B was found distal to the previously used AG splice site þ 100/101. The two genomic breakpoints between positions þ 102 and þ 106 create transcript types A and C, respectively. FIP1L1 exon 13 is not involved in transcript type B as it cannot create an in-frame fusion with the cryptic AG splice sites within PDGFRA exon 12.
The vast majority of patients with transcript type A are created in those regions of PDGFRA where transcript type B is less likely, for example, when PDGFRA breakpoints fell between positions þ 45 and þ 84, transcript type A was found in the majority of patients, whereas transcript type B was created almost exclusively by fusion with FIP1L1 exon 12. Both transcript types should be possible when the PDGFRA breakpoints fall between positions þ 27 and þ 44 of PDGFRA exon 12; however, transcript type B is created in over 80% of patients. This is most likely explained by the constraints on the breakpoint positions for transcript type A required to create a productive inframe mRNA fusion, whereas the breakpoints can be much more variable for the creation of transcript type B. For transcript type C, the constraints are even tighter as the translocation has to generate an in-frame fusion exon without any splicing. Owing to the rarity of this fusion, it is not clear whether any factors might favor the creation of this transcript type but it appears that they are formed in regions where production of transcript type B is not possible.
DNA double-strand breaks (DSBs) are a dangerous threat to genomic integrity and can occur from a variety of exogenous agents (for example, ionizing radiation, topoisomerase IIspecific drugs) or endogenous DNA-damaging lesions (for example, V(D)J recombinase, reactive oxygen species). 20 There are two main hypotheses that have been put forward to explain how DSBs are formed: They could simply represent completely random events and thus, leukemia-associated fusion genes would be a consequence of biological selection for oncogenic products. Alternatively, DSBs might preferentially occur at particular genomic regions as they result from mechanisms that use either specific sequence targets or sequence-dependent secondary structures.
In mammalian cells, repair of DSB is performed by two competing mechanisms: homologous recombination, which requires regions of homology at the breakpoints, and NHEJ in which two non-homologous broken ends are ligated together. Because DSBs are often staggered, NHEJ is frequently associated with small deletions, duplications or insertions at the breakpoints. [21] [22] [23] Chromosome translocations in myeloid disorders generally show features of NHEJ, for example, rearrangements of the MLL and NUP98 genes, [23] [24] [25] the t(15;17), t(8;21) and inv(16) in acute myeloid leukemia [26] [27] [28] [29] and the t(9;22) in chronic myeloid leukemia. 30 After repair, the newly created chimeric sequence has to fulfill several structural and functional requirements to be translated into a protein with oncogenic properties: first, the transcribed mRNA sequence has to be in-frame, which is facilitated by the use of cryptic AG splice sites by the cellular splicing machinery as discussed above. Both fusion partners have to retain the critical functional domains required for malignant transformation, for example, in the case BCR-ABL1, BCR must provide an oligomerization domain, whereas the complete tyrosine kinase domain has to be retained within ABL1. As mentioned, it is much less clear what particular FIP1L1 domains are essentially required for PDGFRA activation, although the disruption of the autoinhibitory WW-like domain seems to be the most likely candidate. FIP1L1-PDGFRA forms by an intrachromosomal deletion rather than a translocation but the sequence features at the genomic breakpoint junctions are also consistent with NHEJ following two DSBs. Statistical analyses provided some evidence for clustering of breakpoints within FIP1L1 that may be related to DNA-or chromatin-related structural features. Significant clustering was evident for all breakpoints when considered together, and also for type B breakpoints considered in isolation. No evidence for clustering of FIP1L1 breakpoints in type A or C cases was found; however, type A breakpoints were associated with predicted scaffold attachment regions, and within the PDGFRA breakpoint cluster region, type A breakpoints formed a single cluster proximal to a scaffold attachment region. Type B FIP1L1 breakpoints did not cluster near any of the structural features, but generally fell within introns close to exons 11, 12 or 13. The observed statistical clustering of type B breakpoints may therefore be governed by gene structure (that is, proper splicing and open-reading frame) and specifically Figure 6 Correlation between the size of the FIP1L1 intron and the number of breakpoints falling within that intron.
Anatomy of the FIP1L1-PDGFRA fusion gene C Walz et al the positions of exon-intron boundaries rather than chromatin/ DNA structural features. In addition to providing information relevant for the molecular diagnosis of FIP1L1-PDGFRA-positive disease, our findings are relevant to the design of strategies to detect minimal residual disease by RT-PCR. Although nine different FIP1L1 exons were found to be fused with the truncated PDGFRA exon 12, only four FIP1L1 exons (exons 10-13) are involved in the vast majority of patients (100/113, 88%; Table 1 ). Jovanovic et al. 6 developed a sensitive quantitative RT-PCR assay with FIP1L1 primers covering FIP1L1 exons 9-13 and a reverse PDGFRA primer overlapping exon 13/14. Only 19 of the 113 (17%) patients in this study could not be detected by this assay due to FIP1L1 breakpoints downstream of FIP1L1 exon 13.
In summary, our results demonstrate that the marked heterogeneity of the FIP1L1-PDGFRA fusion gene is not a random event. The location of the genomic breakpoint within a very short stretch of 94 bp within PDGFRA exon 12 and certain characteristics within FIP1L1 (intron size, structural features and availability of AG splice sites) determine the anatomy of the fusion gene, which is created by illegitimate NHEJ. Because the PDGFRA breakpoint cluster region is constrained by functionally relevant domains for the fusion gene, alternative genomic PDGFRA breakpoints seem unlikely. The great variability in the anatomy of the FIP1L1-PDGFRA fusion gene has important implications for strategies to detect the fusion in patients at diagnosis and also for the development of quantitative RT-PCR assays to monitor response to treatment with TK inhibitors.
